S*BIO Collaborates With Singapore Hospital To Explore JAK2 Inhibitor Pathway

PERTH, Australia - Singapore-based S*BIO signed a collaboration agreement with Tan Tock Seng Hospital in Singapore to evaluate therapeutic effects of its JAK2 inhibitor SB1518 on biological samples from patients with myeloproliferative neoplasms, S*BIO announced Dec. 19